Cargando…

KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia-Robledo, Juan Esteban, Rosell, Rafael, Ruíz-Patiño, Alejandro, Sotelo, Carolina, Arrieta, Oscar, Zatarain-Barrón, Lucia, Ordoñez, Camila, Jaller, Elvira, Rojas, Leonardo, Russo, Alessandro, de Miguel-Pérez, Diego, Rolfo, Christian, Cardona, Andrés F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808025/ https://www.ncbi.nlm.nih.gov/pubmed/35098800 http://dx.doi.org/10.1177/17534666211066064

Ejemplares similares

p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2021)

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)
por: Raez, Luis E., et al.
Publicado: (2022)

Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
por: Ordóñez-Reyes, Camila, et al.
Publicado: (2022)

When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review
por: Rodríguez, July, et al.
Publicado: (2021)

Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab
por: Burgos, Remberto, et al.
Publicado: (2022)

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab
por: Cardona, Andrés F., et al.
Publicado: (2021)

Atypical Skin Manifestations During Immune Checkpoint Blockage in Coronavirus Disease 2019–Infected Patients With Lung Cancer
por: Rolfo, Christian, et al.
Publicado: (2020)

Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
por: Cardona, Andrés F., et al.
Publicado: (2020)

Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies
por: Sotelo-Rodríguez, Diana Carolina, et al.
Publicado: (2019)

Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America
por: Ruiz-Patiño, Alejandro, et al.
Publicado: (2020)

Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab − Diagnostic and Therapeutic Challenge: A Case Report
por: Cardona, Andrés F., et al.
Publicado: (2020)

Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2020)

Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
por: Chamorro, Diego F., et al.
Publicado: (2023)

Response rate of patients with baseline brain metastases from recently diagnosed non‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status
por: Arrieta, Oscar, et al.
Publicado: (2020)

Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2020)

Comprehensive review of fetal adenocarcinoma of the lung
por: Ricaurte, Luisa María, et al.
Publicado: (2018)

Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors
por: Rojas, L., et al.
Publicado: (2022)

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
por: Russo, Alessandro, et al.
Publicado: (2020)

Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP‐LATimus)
por: Martín, Claudio, et al.
Publicado: (2021)

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
por: Ruiz‐Patiño, Alejandro, et al.
Publicado: (2019)

Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado
por: Cañas, Alejandro, et al.
Publicado: (2022)

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)
por: Cardona, Andrés F., et al.
Publicado: (2019)

Immunotherapy Resistance in Non-Small Cell Lung Cancer: A Rubik's Cube to Assemble
por: Rolfo, Christian, et al.
Publicado: (2021)

Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
por: Cifuentes, Claudia, et al.
Publicado: (2023)

Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses
por: Barrios-Bernal, Pedro, et al.
Publicado: (2022)

Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy
por: Barrón, Feliciano, et al.
Publicado: (2020)

Integration of artificial intelligence and precision oncology in Latin America
por: Sussman, Liliana, et al.
Publicado: (2022)

Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib
por: Cardona, Andrés F., et al.
Publicado: (2019)

A New Generation of Vaccines in the Age of Immunotherapy
por: Addeo, Alfredo, et al.
Publicado: (2021)

Effect of the all-trans retinoic acid on neural growth factor serum levels (NGF) and chemotherapy induced neuropathy in patients with advanced lung cancer
por: Arrieta, Oscar, et al.
Publicado: (2007)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

The blood metabolome of incident kidney cancer: A case–control study nested within the MetKid consortium
por: Guida, Florence, et al.
Publicado: (2021)

A Methodological Approach to the Learning of Robotics with EDUROSC-Kids
por: Patiño-Escarcina, Raquel E., et al.
Publicado: (2021)

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
por: Cardona, Andrés F., et al.
Publicado: (2016)

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary
por: Palma, Norma A., et al.
Publicado: (2014)

Targeting the ‘Undruggable’ Driver Protein, KRAS, in Epithelial Cancers: Current Perspective
por: Lam, Kuen Kuen, et al.
Publicado: (2023)

Cracking KRAS(G12C) across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
por: Bhamidipati, D., et al.
Publicado: (2023)

Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib()()()
por: Cuneo, Kyle C., et al.
Publicado: (2018)

MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
por: Lu, Daniel, et al.
Publicado: (2022)

Kids at Risk
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_eojgkolaic4re9l0fmbvs251po